Pembrolizumab (Anti-PD-1) and AMG386 (Angiopoietin-2 (Ang-2) in Patients With Advanced Solid Tumor
Dana-Farber Cancer Institute
Dana-Farber Cancer Institute
MacroGenics
National Cancer Institute (NCI)
Tempus AI
Vedanta Biosciences, Inc.
Eisai Inc.
Day One Biopharmaceuticals, Inc.
Hoffmann-La Roche
Palleon Pharmaceuticals, Inc.
Incyte Corporation
Incyte Corporation
NRG Oncology
NGM Biopharmaceuticals, Inc
Incyte Corporation
Seagen Inc.
University of Pittsburgh
BerGenBio ASA
Stanford University
Novartis
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
AstraZeneca
National Cancer Institute (NCI)
Pfizer
ADC Therapeutics S.A.
Exelixis
Pfizer
Eli Lilly and Company
NextCure, Inc.
Eisai Inc.
Stanford University
Nektar Therapeutics
Nektar Therapeutics
Herlev Hospital
Karyopharm Therapeutics Inc
Ludwig Institute for Cancer Research
Incyte Corporation
Pfizer
Incyte Corporation
Novartis
National Institutes of Health Clinical Center (CC)
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Incyte Corporation
Eli Lilly and Company
National Institutes of Health Clinical Center (CC)
Icahn School of Medicine at Mount Sinai
University of California, San Francisco
Genentech, Inc.
Stanford University
Plexxikon
EMD Serono